"Pending
the completion of CREST-2, we think that it
would be desirable for interventionists and surgeons
to forgo stenting and endarterectomy in
low-risk asymptomatic patients outside that trial.
This restraint would not only spare patients
from procedures that may be unnecessary, but it
should also facilitate early completion of the
trial (and so avoid the fate of SPACE-2), so that
it may be possible to identify which patients will
benefit from an intervention rather than medical
therapy alone in an evidence-based rather than
an eminence-based manner."
http://www.ncbi.nlm.nih.gov/pubmed/26890473
The only advice is: take a second advice!
"Evidence now suggests that the annual rate of
ipsilateral stroke may be as low as 0.5 to 1%8
— a rate that is very similar to that observed in
ACT I and CREST after successful stenting or
endarterectomy."
The other issue about carotid plaque is to assess the status of the plaque surface. For instance in ACS a small trial is testing DAPT instead of stents:
http://www.medscape.com/viewarticle/868367?src=wnl_tp10n_161007_mscpedit_ous&uac=7267HX&impID=1210486
https://clinicaltrials.gov/show/NCT02041650?link_type=CLINTRIALGOV&access_num=NCT02041650
samedi 27 août 2016
Inscription à :
Publier les commentaires (Atom)
Aucun commentaire:
Enregistrer un commentaire